A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose-escalation Trial of BI 765049 and BI 765049 + Ezabenlimab Administered by Parenteral Administration(s) in Patients With Malignant Solid Tumors Expressing B7-H6
Latest Information Update: 14 Aug 2024
At a glance
- Drugs BI 765049 (Primary) ; Ezabenlimab (Primary)
- Indications Carcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 24 Jul 2024 Planned number of patients changed from 120 to 248.
- 04 Mar 2024 Planned End Date changed from 31 May 2025 to 31 Dec 2028.
- 04 Mar 2024 Planned primary completion date changed from 31 May 2025 to 23 Dec 2025.